登入選單
返回Google圖書搜尋
其他書名
Lipid Disorders
出版CSF Medical Communications, 2003-11
ISBN190506411X9781905064113
URLhttp://books.google.com.hk/books?id=OpXOPAAACAAJ&hl=&source=gbs_api
註釋Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Ezetimibe Editorial: Whilst the evidence-base for lipid-lowering in CVD prevention is huge, much needs to be done to translate this into routine clinical practice. Disease Overview: Raised cholesterol, in particular low density lipoprotein cholesterol (LDL-C), appears to be a pivotal risk factor in the development of coronary heart disease (CHD). Drug Review: Ezetimibe, 10 mg once daily, favourably modifies the lipid profile and therefore offers a useful alternative to patients who cannot tolerate statins or for those with mild hypercholesterolaemia who require modest LDL-C reductions. Improving Practice: The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages. At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals.